NCT02824406

Cerebrovascular Reserve Measurements in Sickle Cell Disease

Cerebrovascular Reserve Measurements in Sickle Cell Disease: an MRI Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The primary aim of this study is to evaluate MRI-based cerebrovascular reserve (CVR) measurements in adult patients with Sickle Cell Disease (SCD). The primary objective is to assess whether there is a correlation between CVR and silent cerebral infarcts (SCIs).

Detailed description

CVR is hypothesized to be impaired in SCD patients and could account for the white matter hyperintensities seen on MRI in these patients. Cerebral blood flow (CBF) alone is not sufficient to provide insight into the hemodynamic status of the brain. CVR allows us to gain insight into the capacity of the cerebrovasculature to respond to increased CBF. Vasculopathy is common in SCD and the caliber of the vessels can be assessed with 4D Flow MRI in response to actue and chronic changes in the velocity and wall shear stress on the intracranial arteries in the Circle of Willis. This study will be performed as a single center, patient-control, cross-sectional, observational study in patients with steady-state SCD and controls. The investigators expect that patients with impaired CVR will have a greater number and/or volume of SCIs.

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
DRUG	Acetazolamide	Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.

Timeline

• Start date: 2014-08-01
• Primary completion: 2017-06-01
• Completion: 2017-12-01
• First posted: 2016-07-06
• Last updated: 2016-07-06

Locations

1 site across 1 country: Netherlands